Sasha Huhalov

Sasha has over 16 years of industry experience in both biotech and pharma driving innovation and development of cancer therapeutics and currently leads External Innovation Strategy, Search and Evaluation efforts for Oncology, Cell Therapy, and Global Biologics at Takeda. Prior to joining Takeda Sasha was Head of Portfolio Assessment at Tesaro (acquired by GSK), which focused on interpreting the in-line strategy and external oncology landscape to identify risks and opportunities impacting the internal research, development, and global commercial strategy. Her team actively contributed to the strategies leading to approval of two oncology programs, ZEJULA and JEMPERLI, as well as a number of programs currently in late-stage clinical development. Before joining Tesaro, Sasha worked in various R&D roles at Merrimack Pharmaceuticals. Sasha completed her PhD and post-doctoral work at University College London, focusing on antibody engineering of novel cancer therapeutics.